Form 4: Akero Therapeutics CTO Sells Shares to Cover Tax Obligations

Akero Therapeutics' Chief Technology Officer, Scott A. Gangloff, sold 848 shares of common stock for tax withholding purposes related to restricted stock unit vesting.

Summary

• Scott A. Gangloff, Chief Technology Officer of Akero Therapeutics, Inc. (AKRO), sold 848 shares of the company's common stock.
• The transaction occurred on June 18, 2025, at a weighted-average price of $54.84 per share, with prices ranging from $54.73 to $54.84.
• This sale was non-discretionary and executed to cover tax withholding obligations associated with the vesting of restricted stock units, as per the issuer's "sell-to-cover" policy.
• Following this transaction, Mr. Gangloff directly beneficially owns 23,452 shares of Akero Therapeutics common stock.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary "sell-to-cover" for tax purposes related to RSU vesting, which is a neutral event and does not indicate positive or negative sentiment regarding the company's performance or outlook.

Future Outlook

NA

Management Comments

• The sale represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units.
• The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person.
• Such sales were automatic and not at the discretion of the Reporting Person.

Industry Context

This Form 4 filing details a routine insider transaction for tax purposes, which is a common occurrence across various industries when executives' restricted stock units vest. It does not provide broader industry insights or trends.

Stakeholder Impact

• Shareholders: Minimal impact, as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in management's confidence or company fundamentals.
• Employees: No direct impact beyond the reporting person.

Key Dates

Keywords

Akero Therapeutics, AKRO, Scott A. Gangloff, Chief Technology Officer, CTO, Insider Trading, SEC Form 4, Stock Sale, Restricted Stock Units, RSU, Tax Withholding, Sell-to-Cover